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Doxorubicin- and paclitaxel-selected variants of an in vitro invasive clonal population of the human breast cancer cell line, MDA-MB-
435S, were established by pulse selection, and exhibited a novel ‘superinvasive’ phenotype. This phenotype is characterised by an
ability to relocate to another surface following invasion through matrigel and membrane pores, by decreased adhesion to
extracellular matrix proteins and by increased motility. This may represent an in vitro model of a step in the metastatic process
occurring subsequent to invasion. The paclitaxel-resistant variants, MDA-MB-435S-F/Taxol-10p and MDA-MB-435S-F/Taxol-10p4p
were resistant to paclitaxel, vincristine and docetaxel, but not to doxorubicin, carboplatin, etoposide or 5-fluorouracil. The
doxorubicin-selected variants MDA-MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10p10p, in contrast, exhibited only small
increases in resistance to doxorubicin, although they were slightly resistant to VP-16 and docetaxel, and exhibited increased sensitivity
to paclitaxel, carboplatin and 5-fluorouracil.
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Invasion and metastasis are intimately involved in the pathology of
cancer, but the biological and molecular natures of these
phenomena remain incompletely understood. A possible associa-
tion exists between multiple drug resistance and invasive potential
in carcinoma cells (Liang et al, 2001, 2002).
The majority of previous studies focus on the direct effect of
drug exposure on the invasive potential (invasion in the presence
of the drug), as opposed to the long-term effects of drug treatment
on the invasive phenotype of cell, coupled with emerging drug
resistance. While a few reports indicate that paclitaxel exposure
increases motility and invasion (Welch et al, 1989; Silbergeld et al,
1995), others indicate an inhibitory effect on invasion (Westerlund
et al, 1997; Sgadari et al, 2000). Silbergeld et al (1995) reported that
increasing the paclitaxel concentration caused increased locomo-
tion in glioblastoma cell lines. Welch et al (1989) showed that
pretreatment of cell lines, with low and high invasive potentials,
with vincristine, colcemid, or colchicine (but not paclitaxel), at
noncytotoxic levels, resulted in inhibition of invasion. Westerlund
et al (1997) showed that OVCAR-3 cell attachment, migration and
in vitro invasion were significantly decreased after paclitaxel
treatment. Sgadari et al (2000) found that paclitaxel promoted
regression of Kaposi’s sarcoma (KS) lesions in vivo and that it
blocked the growth, migration, and invasion of KS cells in vitro.
Doxorubicin appears to have an inhibitory effect on invasion
(Repesh et al, 1993; Hikawa et al, 2000).
Previous studies in this laboratory showed that selection of
RPMI 2650, a noninvasive cell line, with the chemotherapeutic
agents paclitaxel and melphalan, resulted in multiple drug-
resistant phenotypes and in the case of melphalan but not
paclitaxel, a highly invasive phenotype (Liang et al, 2001). To
further investigate the effects of chemotherapeutic drug selection,
in particular doxorubicin and paclitaxel, and the effect of these
drugs on adhesive, locomotive and invasive phenotypes, paclitaxel-
and doxorubicin-selected variants of the human breast cell line
MDA-MB-435S-F were established.
MATERIALS AND METHODS
Chemicals
Paclitaxel and VP-16 were obtained from Bristol-Myers Squibb
(Dublin, Ireland), doxorubicin and 5-fluorouracil (5-FU) from
Farmitalia Carlo Erba (Milton Keynes, UK), docetaxel from
Aventis (France) and vincristine from Lederle (Dublin, Ireland).
All media and serum used in the maintenance of the cell lines were
obtained from Sigma Aldrich (Dublin, Ireland). Unless stated, all
other chemicals were obtained from Sigma (Dublin, Ireland).
Cell lines
The human breast cancer cell line MDA-MB-435S was obtained
from the American type culture collection (ATCC) and was main-
tained in culture at 371C using RPMI supplemented with 2mM
L-glutamine (Gibco) and 10% foetal calf serum. MDA-MB-435S
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yis a spindle-shaped strain which evolved from the parental line
MDA-MB-435 isolated by Cailleau et al (1978), derived from the
pleural effusion of a 31-year-old female with metastatic, ductal
adenocarcinoma of the breast. MDA-MB-435S-F was obtained by
clonal dilution from MDA-MB-435S in this laboratory. The MDA-
MB-435S-F doxorubicin- or paclitaxel-resistant variants were
derived by pulse selection of the parental cells with the IC90 value
of doxorubicin or paclitaxel. Cells were exposed to the IC90 value of
15ngml
 1 paclitaxel for 4h, once a week for 10 weeks (MDA-MB-
435S-F/Taxol-10p). These cells were then exposed to 125ngml
 1
paclitaxel for 4h, once a week for 4 weeks (MDA-MB-435S-F/
Taxol-10p4p). Cells were also exposed to the IC90 value of
120ngml
 1 doxorubicin for 4h, once a week for 10 weeks
(MDA-MB-435S-F/Adr-10p). These cells were then exposed to a
further 10 pulse with 200ngml
 1 doxorubicin for 4h, once a week
for 10 weeks (MDA-MB-435S-F/Adr-10p10p). Antibiotics were not
used in the growth media. All cell lines were free from mycoplasma
as tested with the indirect Hoechst DNA staining method.
Western blotting
Western blotting was performed by the method of Moran et al
(1992). Cdc-42, Rho A, Rac1, MMP-2, c-Met, IGF-1R Pgp, MRP1,
EGFR, HER2, HER3 and HER4 were detected by Western blotting
with polyclonal antibodies AB4201, AB19016, monoclonal anti-
bodies MAB3735 (Chemicon, UK), polyclonal antibody sc-28,
sc-713 (Santa Cruz Biotechnology, USA), monoclonal antibodies
ALX-801-002 and ALX-801-007 (Alexis, UK), monoclonal MS-400-
P1, MS-327-P, MS-313-P and polyclonal antibodies RB-284-P
(Neomarkers, USA), respectively. Secondary antibodies rabbit anti
mouse-HRP (P0260), goat anti-rabbit-HRP (P0448) and rabbit
anti-Rat-HRP (P0450) were obtained from Dako (Germany).
Cytotoxicity assays
Cytotoxicity testing of drugs was measured by colorimetric assays
as previously described (Martin and Clynes, 1991, 1993; Duffy et al,
1998). Briefly on day 1, cells were seeded at 1 10
3 cells/well in a
96-well plate and allowed to attach overnight in a 5% CO2
incubator at 371C. The appropriate concentrations of drug were
added to the plate on day 2, and the assay was terminated on day 7.
All assays were performed in triplicate.
Quantification of doxorubicin accumulation in MDA-MB-
435S-F
The level of doxorubicin in DLKP cells was quantified using liquid
– liquid extraction and reverse-phase high-performance liquid
chromatography (HPLC) analysis as previously described in Duffy
et al (1998).
Adhesion assays
Adhesion assays were performed using the method of Torimura
et al (1999). 24-well plates were coated with 250mlo f2 5 mgml
 1
collagen type IV, fibronectin and laminin and 250ml of 1mgml
 1
Matrigel and incubated overnight at 41C. A volume of 0.5ml of a
sterile 0.1% BSA/PBS solution was dispensed into each well to
reduce nonspecific binding. The plates were incubated at 371C for
20min and then rinsed twice with PBS. Cells were resuspended in
serum-free RPMI medium and plated at a concentration of
2.5 10
4cellswell
 1 in triplicate and incubated at 371C for
60min. Control wells were those that had been coated but
contained no cells. After 60min, the medium was removed from
the wells and rinsed gently with PBS. This was then removed and
200ml of freshly prepared phosphatase substrate (10mM p-
nitrophenol phosphate in 0.1 M sodium acetate, 0.1% Triton X-
100, pH 5.5) was added to each well. The plates were then
incubated in the dark at 371C for 2h. The enzymatic reaction was
stopped by the addition of 100mlo f1N NaOH. 100ml aliquots were
transferred to a 96-well plate and read in an ELISA reader at
405nm with a reference wavelength of 620nm.
Invasion assays and motility assays
Invasion assays were performed by a modification of the method
described by Albini et al (1991). Matrigel was diluted to 1mgml
 1
in serum-free DMEM medium. A volume of 100ml of 1mgml
 1
Matrigel was placed into each insert (Falcon) (8.0mm pore size),
which stood in wells of a 24-well plate (Costar). The inserts and the
plate were incubated overnight at 41C. The following day, cells
were harvested and suspended in RPMI 1640 containing 10% FCS
at a concentration of 1 10
6cellsml
 1. The inserts were washed
with serum-free RPMI 1640, then 100ml of the cell suspension was
added to each insert and 250ml of RPMI 1640 containing 10% FCS
was added to the insert well. Cells were incubated at 371C for 48h.
After this time period, the inner side of the insert was wiped with a
wet swab to remove the cells, while the outer side of the insert was
gently rinsed with PBS and stained with 0.25% crystal violet for
10min, rinsed again and then allowed to dry. The surface of the 24-
well plate was rinsed gently twice with PBS and stained with 0.25%
crystal violet for 10min, rinsed again and then allowed to dry. Cells
were quantified by both counting with the aid of a light microscope
and eluting the stain with 200ml 33% glacial acetic acid. Aliquots
(100ml) were transferred to a 96-well plate and read in an ELISA
reader at 570nm with a reference wavelength of 620nm. The
procedure for carrying out motility assays was identical to the
procedure used for invasion assays with the exception that the
inserts were not coated with Matrigel.
Gelatin zymography
Zymography was used to assess the level of proteolytic activity of
different proteases. Gelatin is a substrate for MMPs, serine and
cysteine proteases. The protein concentration of the serum-free
medium in which cells were cultured was determined by the Biorad
protein assay (Biorad) and 20mg of supernatant protein was
applied to nonreduced sodium dodecyl sulphate – polyacrylamide
gel electrophoresis (SDS – PAGE) using a 10% gel containing 0.1%
gelatin. After electrophoresis, gels were soaked in 2.5% Triton X-
100 at room temperature with gentle shaking for 30min and
incubated in substrate buffer7EDTA (50mM Tris-HCl, pH 8.0,
5m M CaCl2)a t3 7 1C for 18–24h. Gels were then stained with
2.5mgml
 1 Coomassie Blue for 2h and destained in a mixture of
acetic acid:isopropanol: distilled water (1:3:6) until clear bands
were visible. Gelatinase activity was determined as distinct, clear
bands. Each zymograph was carried out three times.
Statistical analysis
Analysis of the significance of the difference in the mean IC50 value
calculated from toxicity assays were performed using a paired
Student’s t-test, which was run on Sigma Plot. A P-value 40.05
was deemed not significant. A P-value o0.05 was deemed
significant. A P-value o0.005 was deemed highly significant.
RESULTS
Motility and invasion assays
Figure 1 describes the invasive and locomotive capabilities of
MDA-MB-435S-F. Figure 1 shows that MDA-MB-435S-F is highly
invasive, but selection with paclitaxel or doxorubicin results in a
more aggressive invasive phenotype characterised by a proportion
of the invading cells detaching from the bottom of the insert and
reattaching to the bottom of the 24-well plate (superinvasion),
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ywhich was negligible in MDA-MB-435S-F. This effect was greater
for the paclitaxel-selected than doxorubicin-selected variants. In
vitro invasiveness for the positive control cell line RPMI-2650Ml
and negative control cell line RPMI-2650 (Liang et al, 2001) gave
expected results (results not shown) and the superinvasive
phenotype was not observed in the positive control. Motility
assays in Figure 1 show that MDA-MB-435S-F is motile. The
motility of both the paclitaxel- and the doxorubicin-selected
variants were found to have further increased. In contrast to what
was observed in invasion assays, following motility assays, a
proportion of parental MDA-MB-435S-F cells had detached from
the bottom of the insert and reattached to the bottom of the 24-
well plate. This effect was also observed in the drug-selected
variants.
Adhesion assays
Paclitaxel- or doxorubicin-selection of MDA-MB-435S-F results in
decreased adhesion to fibronectin, laminin, collagen type IV and
Matrigel (Figure 2). This decrease is more apparent in paclitaxel-
selected cell lines than in doxorubicin-selected cell lines (mirroring
the degree of expression of the superinvasive phenotype).
Cross-resistance profiles
The sensitivity of the paclitaxel-selected variants, and the
doxorubicin-selected variants, to a range of chemotherapeutic
agents was determined (Tables 1 and 2). The highest levels of
resistance in the paclitaxel-selected variants were observed with
vincristine, docetaxel and its selecting agent paclitaxel (Table 1). A
low-level resistance to carboplatin and a decreased sensitivity to
5-fluorouracil were observed for MDA-MB-435S-F/Taxol-10p, but
not in MDA-MB-435S-F/Taxol-10p4p. MDA-MB-435S-F/Taxol-
10p4p developed a low-level resistance to doxorubicin. Resistance
to VP-16 was unaltered in these variants. The results (Table 2)
show that MDA-MB-435S-F failed to develop any significant
resistance to doxorubicin by pulse selection, despite the fact that
high cell kill was observed during selection with doxorubicin.
However MDA-MB-435S-F/Adr-10p was found to be marginally
resistant to VP-16 and sensitised to 5-fluorouracil, vincristine and
paclitaxel. No significant change in resistance to carboplatin or
docetaxel was observed. MDA-MB-435S-F/Adr-10p10p exhibited
crossresistance to docetaxel, vincristine, and VP-16, but was
sensitised to paclitaxel, carboplatin and 5-fluorouracil.
Detection of drug efflux proteins Pgp and MRP-1 and
results of doxorubicin efflux studies using HPLC analysis
and circumvention studies with sulindac and verapamil
Figure 3(a) shows that all pulse selected MDA-MB-435S-F variants
exhibit increased levels of Pgp (p-glycoprotein) and MRP-1 by
Western blot. Analysis of doxorubicin uptake and efflux was
carried out on MDA-MB-435S-F variants, using quantification by
HPLC (Figure 3(b)) and all were found to exhibit an increase
(range two- to five-fold; MDA-MB-435S-F/Taxol-10p – 2.1X, MDA-
MB-435S-F/Taxol-10p4p – 5.0X, MDA-MB-435S-F/Adr-10p – 3.6X,
MDA-MB-435S-F/Adr-10p10p – 3.5X) in doxorubicin efflux
compared with the parental cell line. Toxicity assays were
performed with doxorubicin and paclitaxel, combined with either
sulindac (MRP-1 inhibitor) or verapamil (Pgp and MRP-1
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Figure 1 Levels of basic invasion, superinvasion, basic motility and
supermotility are displayed for MDA-MB-435S-F, MDA-MB-435S-F/Taxol-
10p, MDA-MB-435S-F/Taxol-10p4p, MDA-MB-435S-F/Adr-10p and
MDA-MB-435S-F/Adr-10p10p. Results are displayed as the mean number
of cells invading or locomoting7s.d. (n¼3).
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Figure 2 Attachment of the MDA-MB-435S-F cell line and its paclitaxel-
and doxorubicin-selected variants to extracellular matrix (ECM) proteins:
laminin, fibronectin, collagen type IV, and matrigel. Results are expressed as
absorbance at 405nm with a reference wavelength of 620nm. The data
are shown as mean absorbance7s.d. (n¼3).
Table 1 Comparison of chemosensitivity in the MDA-MB-435S-F cell line and its paclitaxel selected variants
a
IC50 (ngml
 1)
Drug
MDA-MB-
435S-F
MDA-MB-435S-
F/Taxol-10p
Fold resistance of
MDA-MB-435S-
F/Taxol-10p
MDA-MB-435S-
F/Taxol-10p4p
Fold resistance of
MDA-MB-435S-
F/Taxol-10p4p
Doxorubicin 27173 242721 0.89 456720** 1.68
Paclitaxel 28.371.52 25973** 9.15 900740** 31.80
Carboplatin 4130071500 5430075100* 1.31 3300073400 0.79
Docetaxel 3.3370.37 12.2370.37** 3.67 62.471.3** 18.73
VP-16 1844777 22257152 1.20 1740717 0.94
5-Fluorouracil 74307680 35007170** 0.47 68307600 0.91
Vincristine 12.971.3 74.670.5** 5.78 176756** 13.64
aThe IC50 values are the mean of a minimum of three repeat experiments. *Po0.05, Student’s t-test. **Po0.005, Student’s t-test.
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enhanced doxorubicin toxicity in all cell lines (parental and
variants), but verapamil had a greater effect than sulindac on all
selected variants. Verapamil (but not sulindac) had an effect on
paclitaxel resistance but only in the paclitaxel-selected variants
(taxanes are known to be poor substrates for MRP-1). Sulindac had
no effect on paclitaxel toxicity in the parental cell line or either of
the doxorubicin-selected variants, but note that these were already
more sensitive to paclitaxel than the parental line. These results
suggested increased activity of at least two efflux pumps as a result
of doxorubicin- and paclitaxel-selection. Doxorubicin net accu-
mulation in the variants was however variable in comparison to
the parental cell line (MDA-MB-435S-F/Taxol-10p – 81.4575.3%,
MDA-MB-435S-F/Taxol-10p4p – 110.78714.1%, MDA-MB-435S-
F/Adr-10p – 128.4175.3%, MDA-MB-435S-F/Adr-10p10p –
97.0676.1%). These results suggest that factors other than efflux
may also play a role in net drug accumulation in these cell lines.
Isolation and morphology of populations of differing
invasive population
Three populations of cells were isolated from MDA-MB-435S-F
and its drug-selected variants. To do this invasion assays were set
up and the cells were allowed to invade for 48h. The three
populations were isolated as follows. Firstly, cells which had not
invaded (noninvasive, NI), were isolated from the inside of the
invasion chamber by pipetting up remaining cells and transferring
to a well containing fresh medium. A second population (invasive,
I) was isolated from the bottom side of the insert by trypsinisation
of cells into a well containing fresh medium. The third population
(superinvasive, SI), that is, those cells which had invaded, detached
from the bottom of the insert and reattached to the bottom of the
24-well plate, were allowed to grow until they reached suitable
confluency levels for further subculturing. No differences were
observed in the morphology of the three invasive populations
isolated, except for an increased tendency of invasive and
superinvasive cells to grow in clumps even at subconfluency.
Invasiveness of isolated populations
Invasion assays were performed to compare the invasiveness of the
three populations isolated from MDA-MB-435S-F and its multiple
drug-resistant (MDR) variants. Figure 4(a) represents the levels of
cell invasion to the underside of the invasion chamber (basic
invasion). The SI cell populations displayed the greatest invasion
to this point. Surprisingly, the NI populations displayed invasion
similar to the isolated I populations, to the underside of the
invasion chamber. Figure 4(b) (a superinvasion assay) represents
the relative numbers of cells that relocated to the surface of the 24-
well plate after invasion through the invasion chamber. Here, as is
the case with motility assays (Figure 5), invasion was greatest in
the SI populations with the exception of MDA-MB-435S-F/Taxol-
10p4p. In contrast to Figure 4(a), the I populations displayed
greater superinvasion than the NI populations to the surface of the
24-well plate. The SI populations (again with the exception of the
MDA-MB-435S-F/Taxol-10p4p SI population) were the most
invasive.
Motility of isolated populations
Motility assays were performed to compare the motility of
the three populations isolated from MDA-MB-435S-F and its
doxorubicin- and paclitaxel-selected variants. Figure 5(a)
represents the levels of cell migration to the underside of the
motility chamber (basic motility). Figure 5(b) represents the
levels of cell relocation to the surface of the 24-well plate after
migration through the motility chamber (supermotility). These
Table 2 Comparison of chemosensitivity in the MDA-MB-435S-F cell line and its doxorubicin selected variants
a
IC50 (ngml
 1)
Drug
MDA-MB-
435S-F
MDA-MB-435S-
F/Adr-10p
Fold resistance of
MDA-MB-435S-F/Adr-10p
MDA-MB-435S-
F/Adr-10p10p
Fold resistance of
MDA-MB-435S-F/Adr-10p10p
Doxorubicin 27173 316715 1.16 381711.54** 1.40
Paclitaxel 28.371.52 20.372.1* 0.71 17.670.2* 0.62
Carboplatin 4130071500 3760071150 0.91 2460071520* 0.59
Docetaxel 3.3370.37 3.7670.20 1.12 4.7670.152* 1.42
VP-16 1844777 26637148** 1.44 3785779** 2.05
5-Fluorouracil 74307680 33607400* 0.45 3430750* 0.46
Vincristine 12.971.3 6.970.69** 0.53 32.172.5** 1.61
aThe IC50 values are the mean of a minimum of three repeat experiments. *Po0.05, Student’s t-test. **Po0.005, Student’s t-test.
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Figure 3 Expression of (A) drug efflux associated proteins, Pgp and
MRP1, and levels of (B) doxorubicin accumulation and efflux (7s.d.; n¼3)
in MDA-MB-435S-F and its doxorubicin- and paclitaxel-selected variants.
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yfigures indicate a general trend for increased motility in the SI
populations vs NI or I, with the exception of the MDA-MB-435S-F/
Taxol-10p4p SI population.
Adhesion of superinvasive populations to ECM
components in comparison to parental populations
Figure 6 shows that the adhesion of the paclitaxel-selected SI
populations to ECM proteins was largely unaltered. In contrast, the
doxorubicin-selected SI populations displayed increased in adhe-
sion, especially to fibronectin, with increased selection.
Gelatin zymography
Zymography was also performed as shown in Figure 7. No
alterations in the levels of MMP activity were found. This shows
that the superinvasive phenotype is not associated with increased
MMP activity. The MDA-MB-435S-F parental cell line and its drug-
selected variants display secreted bands corresponding to pro-
MMP-2 and pro-MMP-9. There are also double bands expressed at
approximately 50–60kDa. A candidate for this is MMP-1, which
runs as a doublet at 52 and 57kDa in their unglycosylated and
glycosylated forms of the proenzyme. Addition of EDTA, a
chelating agent which can bind zinc and calcium which are
needed for the activation of MMPs, to the substrate buffer
eliminates expression of all protease bands, confirming the gelatin
degrading proteases secreted by MDA-MB-435S-F parent and
variants are most probably members of the matrix metalloprotei-
nase family.
Mechanisms of increased superinvasiveness
Figure 8 shows that HER1/EGFR protein expression was increased
with increasing paclitaxel and doxorubicin resistance, while
expression of HER2/c-erbB-2 protein remained unchanged.
HER3 protein expression decreased with increasing paclitaxel
resistance and also with doxorubicin selection. HER4 protein
expression was undetectable in any of the MDA-MB-435S-F
variants.
In order to investigate changes in protein levels that might be
associated with mechanisms for the superinvasive phenotype,
Western blots were performed on the parental cell line, MDA-MB-
435S-F, and two SI populations MDA-MB-435S-F/Taxol-10p4pSI
and MDA-MB-435S-F/Adr-10p10pSI. Proteins included in the
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Figure 5 Comparison of levels of (A) basic motility and (B)
supermotility by noninvasive (NI), invasive (I) and superinvasive (SI)
populations, isolated from MDA-MB-435S-F and its drug-selected variants.
Results are expressed as absorbance at 570nm with a reference
wavelength of 620nm. The data are shown as mean7s.d. (n¼3).
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populations, isolated from MDA-MB-435S-F and its drug-selected variants.
Results are expressed as absorbance at 570nm with a reference
wavelength of 620nm. The data are shown as mean7s.d. (n¼3).
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Figure 6 Comparison of adhesiveness of superinvasive populations
isolated from MDA-MB-435S-F/Taxol-10p, MDA-MB-435S-F/Taxol-10p4p,
MDA-MB-435S-F/Adr-10p and MDA-MB-435S-F/Adr-10p10p to their
mixed populations. Adhesion of the superinvasive populations is displayed
as a percentage of the adhesion levels of their individual mixed
population7s.d. (n¼3).
Paclitaxel and doxorubicin selection induces superinvasion
SA Glynn et al
1804
British Journal of Cancer (2004) 91(10), 1800–1807 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yinvestigation were the Rho-like GTPases, cdc42, RhoA and Rac1,
the growth factor receptors EGFR/HER1, c-Met, and IGF-1R, and
the drug resistance pump MRP1; results are presented in Figure 9.
Levels of Cdc42, Rac1 and RhoA were increased. A 50kDa portion
of c-Met was elevated in MDA-MB-435S-F/Adr-10p10pSI. The IGF-
1R receptor remained unchanged, while HER1/EGFR increased.
MRP1 was also elevated in the SI populations.
DISCUSSION
There have been various reports linking development of resistance
to chemotherapeutic drugs, such as doxorubicin (Giavazzi et al,
1983; Scaddan and Dufresne, 1993), methotrexate (Lucke-Huhle,
1994) and melphalan (Liang et al, 2001), with increased invasive-
ness. The results presented here demonstrate that selection of the
human breast cell line MDA-MB-435S-F with doxorubicin and
paclitaxel resulted in a more aggressively invasive phenotype.
Selection of MDA-MB-435S-F with doxorubicin or paclitaxel had a
dramatic effect on the nature of invasion in this cell line; instead of
the cells invading to the underside of the invasion chamber and
halting at this point (normal invasion), a significant proportion of
the cells, which we term superinvasive cells, were observed to
detach from the underside of the chamber and reattach to the
surface of the 24-well plate. This was not observed with the
parental cell line. Enhanced invasiveness following paclitaxel
treatment was unexpected, in the context of previous published
results (Stearns and Wang, 1992; Terzis et al, 1997; Westerlund
et al, 1997; Liu et al, 1998; Sgadari et al, 2000). The data presented
clearly demonstrate that the superinvasive cells display reduced
attachment to ECM proteins coupled with increased motility. It is
therefore suggested that these phenomenon contribute to the
superinvasive phenotype. The reduction in adhesion was more
apparent in the paclitaxel- than in the doxorubicin-selected
variants, as was the degree of superinvasiveness. No alterations
in the activity of either MMP-2 or MMP-9 were detected. This
result was not unexpected as the parental cells already have the
ability to travel through the Matrigel and the superinvasive
phenotype may essentially involve altered adhesion and motility,
coupled with the ability to survive while unattached.
To further investigate the more aggressive superinvasive
phenotype observed in the doxorubicin- and paclitaxel-selected
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Figure 7 Zymogram of gelatin proteases secreted by MDA-MB-435S-F
and its drug-selected variants in the presence or absence of EDTA, with
BHK as a positive control for the secretion of pro-MMP2 (72kDa), MMP-2
(66kDa), pro-MMP-9 (92kDa) and MMP9 (86kDa).
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Figure 8 Expression of HER receptor proteins, HER1/EGFR, HER2/c-
erbB-2, HER3 and HER4 in MDA-MB-435S-F and its doxorubicin- and
paclitaxel-selected variants. b-Actin is included as a loading control. This gel
is representative of repeat experiments.
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Figure 9 Expression of a range of invasion and motility associated
proteins in MDA-MB-435S-F, MDA-MB-435S-F/Taxol-10p4pSI and MDA-
MB-435S-F/Adr-10p10pSI. a-tubulin and GAPDH are included as a loading
controls. This gel is representative of repeat experiments.
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invasive, SI) were isolated from invasion assays of MDA-MB-435S-
F and its selected variants, where available. Analysis of these
populations revealed no major differences in their morphology,
except that invasive populations tended to clump more. In general,
both motility and invasion levels were greatest in the superinvasive
populations, followed by the invasive populations, with the
noninvading populations being the least motile or invasive;
nevertheless, it should be noted that ‘noninvading’ cell population
still contained cells capable of invading in subsequent assays. The
one exception to this pattern was MDA-MB-435S-F/Taxol-10p4p,
with the invasive populations displaying the greatest motility and
invasion.
This phenomenon of superinvasion, described for the first time
in this paper, may represent an in vitro model for a step in the
metastasis subsequent to invasion, and hence may lead to a better
understanding of the metastatic process.
The Taxol-10p-SI population was less adhesive to the ECM
proteins tested than its parental cell line Taxol-10p which in turn
was less adhesive than the original cell line MDA-MB-435S-F. The
Taxol-10p4p-SI, Adr-10p-SI and Adr-10p10p-SI populations are
more adhesive to ECM proteins tested than their individual
parental cell lines, which in turn are less adhesive than the original
cell line MDA-MB-435S-F.
In order to investigate possible mechanisms of superinvasion,
two of the SI populations, MDA-MB-435S-F/Adr-10p10pSI and
MDA-MB-435S-F/Taxol-10p4pSI, were compared to the parental
cell line MDA-MB-435S-F, for changes in expression at the protein
level, of EGFR, the IGF-1 receptor, c-met, the Rho-GTPases, RhoA,
Rac1 and Cdc42. Results show Cdc42, Rac1 and RhoA protein
increased in the superinvasive populations. Similar patterns have
been observed in Ras-transformed fibroblasts and epithelial cells,
and may indicate Ras activation in the selected cells (Zondag et al,
2000; Sahai et al, 2001). RhoA is involved in the generation of
contractile force and in moving the body and the tail behind the
leading edge. Rac1 is involved in the development of lamellipodia,
and Cdc42 is involved in filopodia formation. A 50kDa truncated
form of c-Met was elevated in MDA-MB-435S-F/Adr-10p10pSI.
C-met plays a role in inducing invasion and motility. Davies et al
(2004) demonstrated that by targeting the HGF/SF receptor c-met
using a hammerhead ribozyme transgene, they could reduce in
vitro invasion and migration in prostate cancer cells. IGFR1-R
levels did not change in the superinvasive variants, but HER1/
EGFR was elevated, as was also seen in MDA-MB-435S-F/Taxol-
10p, MDA-MB-435S-F/Taxol-10p4p, MDA-MB-435S-F/Adr-10p
and MDA-MB-435S-F/Adr-10p10p, where HER1/EGFR protein
was increased and HER3 protein expression was decreased.
HER1/EGFR and HER3 have previously been linked to poor
prognosis and tumour aggressiveness (Tovey et al, 2004; Ueda et al,
2004).
Western blot analysis also indicated elevated levels of both P-gp
and MRP-1 in the drug-selected variants and SI populations. All
the paclitaxel- and doxorubicin-selected variants and SI popula-
tions displayed increased doxorubicin efflux, although this is not
associated with significant increases in resistance in the doxor-
ubicin-selected variants. By extension this increased efflux
may also play a role in paclitaxel resistance in these cell
lines. Associations have been shown previously between P-gp
overexpression and increased invasiveness (Weinstein et al,
1991; Bjornland et al, 1998; Kotchetkov et al, 2003); however,
other studies by Bjornland et al (1998) suggests an association
rather that a mechanistic link between Pgp expression and
invasion.
Sulindac circumvents MRP-1-mediated doxorubicin drug resis-
tance, while verapamil is a modulator of both Pgp- and MRP-1-
mediated drug resistance (Duffy et al, 1998). Both verapamil and
sulindac enhanced doxorubicin toxicity in all cell lines tested.
These results suggest that MRP-1 and Pgp both play a role in
doxorubicin resistance in these cell lines. Verapamil (but not
sulindac) had an effect on paclitaxel resistance in the paclitaxel-
selected variants, suggesting a role for Pgp but not MRP-1
(although it must be remembered, in evaluating these results that
verapamil and sulindac affect other cellular targets (Etievant et al,
1993; Brambilla, 1994; Akashi et al, 2000).
Doxorubicin-resistant cell lines that express MRP-1 are nor-
mally cross-resistant to doxorubicin, daunorubicin, VP-16, and
vincristine, but not to any significant extent to paclitaxel or
vinblastine (Haimeur et al, 2004). Paclitaxel resistant cell lines that
overexpress Pgp are normally cross-resistant to doxorubicin,
vincristine, vinblastine, VP-16 and show little or no cross
resistance to alkylating agents, platinum drugs and antimetabolites
(Sun et al, 2004). The paclitaxel-resistant variants discussed here
do not display a MDR profile consistent with classic Pgp conferred
drug resistance. This resistance profile is more consistent with
changes in microtubule expression. These results taken together
suggest multiple changes in gene expression in the drug-selected
cells.
In summary, the results presented here indicate that exposure of
the human breast cell line MDA-MB-435S-F to doxorubicin or
paclitaxel can result in an aggressive in vitro phenotype not
previously described, and which may be a useful model for
investigation of a postinvasion step in the metastatic process.
While our results suggest that the invasive and superinvasive
phenotypes retain their aggressive phenotypes following invasion,
we also showed that the noninvasive cells isolated from the wells
could subsequently generate invasive and superinvasive popula-
tions. This concurs with the complex nature of the invasive
phenotype and the apparent ability of the phenotype to revert as
evidenced by phenomena such as dormancy of micrometastasis
(Naumov et al, 2001) and the inefficiency of the metastatic process
(Chambers et al, 2002).
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